Abstract: In accordance with embodiments, there are provided mechanisms and methods for cloning a child object with a parent object. These mechanisms and methods for cloning a child object with a parent object can provide improved functionality of the cloning process. Namely, the cloning of the child record with the cloning of the parent record may prevent the requirement that parent and child records be cloned via separate cloning processes.

Abstract: The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies.

Abstract: The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.

Abstract: The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

Abstract: A method of controlling a remote monitoring device from a vehicle includes sending a command signal from a telematics unit via a wi-fi connection to the remote monitoring device and receiving data from the remote monitoring device via a wi-fi connection at the telematics unit. The data is sent to a destination via a wireless network.

Abstract: A system employing a vehicle module, and an intelligent connector in communication with the vehicle module implements a method for controlling the vehicle module. First, the intelligent connector receives a wireless transmission of a command signal. Second, the intelligent connector determines one or more control actions responsive to the command signal. Finally, the intelligent connector communicates one or more control signals indicative of the control action(s) to the vehicle module.

Abstract: The present invention provides a method for managing telematics unit within a telematics equipped mobile vehicle based on vehicle power level. The method includes receiving at least one mobile vehicle sensor input, determining a mobile vehicle system power value based on the at least one received vehicle sensor input, and operating the telematics unit based on the determined mobile vehicle system power value. The step of operating the telematics unit based on the determined mobile vehicle system power value may include comparing the determined mobile vehicle system power value to a mobile vehicle system target power level, determining if the difference between the mobile vehicle system power value and the mobile vehicle system target power level exceeds a system power level threshold, and initiating a standard operating mode interrupt when the system power level threshold is exceeded.

Abstract: This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —NR4R5, —C(?O)R5, —C(?O)C(?O)R5, —C(?O)NR4R5, —C(?O)OR5, —O(C?O)NR4R5, or

Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.